GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines

Phase 3

Completed

Conditions: Infections, Rotavirus

First Posted Date: 2006-08-31

Last Posted Date: 2017-03-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 400

Registration Number: NCT00370318

Locations: 🇨🇿
GSK Investigational Site, Znojmo, Czech Republic

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Infections, Streptococcal

First Posted Date: 2006-08-31

Last Posted Date: 2016-10-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 390

Registration Number: NCT00370227

Locations: 🇫🇮
GSK Investigational Site, Vantaa, Finland

Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Prevenar
Biological: Synflorix
Biological: Infanrix hexa

First Posted Date: 2006-08-31

Last Posted Date: 2019-06-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1200

Registration Number: NCT00370396

Locations: 🇵🇱
GSK Investigational Site, Siemianowice Slaskie, Poland

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: pazopanib

First Posted Date: 2006-08-31

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT00370513

Locations: 🇨🇳
GSK Investigational Site, Taipei, Taiwan

Study to Assess the Effect Of Alosetron On Mucosal Blood Flow

Phase 4

Completed

Conditions: Irritable Colon

First Posted Date: 2006-08-30

Last Posted Date: 2015-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 49

Registration Number: NCT00370032

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Spacer Comparison In Adult Asthmatics

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2006-08-30

Last Posted Date: 2016-10-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00369993

Locations: 🇳🇿
GSK Investigational Site, Wellington, New Zealand

FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: FLOVENT (fluticasone propionate) HFA
Drug: Placebo HFA

First Posted Date: 2006-08-30

Last Posted Date: 2017-09-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00370097

Locations: 🇺🇸
GSK Investigational Site, Dallas, Texas, United States

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Phase 3

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: Different formulations of GSK Biologicals' HPV vaccine (580299)
Biological: Menactra TM
Biological: Boostrix TM

First Posted Date: 2006-08-29

Last Posted Date: 2018-07-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1330

Registration Number: NCT00369824

Locations: 🇺🇸
GSK Investigational Site, Vienna, Virginia, United States

Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects

Phase 3

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Dutasteride
Drug: Placebo

First Posted Date: 2006-08-29

Last Posted Date: 2018-09-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 378

Registration Number: NCT00368979

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

A Local Register Study For Major Depression Of Paroxetine Controlled Release

Phase 3

Completed

Conditions: Depressive Disorder, Major
Major Depressive Disorder (MDD)

First Posted Date: 2006-08-24

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 362

Registration Number: NCT00368303

Locations: 🇨🇳
GSK Investigational Site, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy